Anti-Obesity Prescription Drugs-Global Market Status and Trend Report 2013-2023
Report Summary
Anti-Obesity Prescription Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-Obesity Prescription Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Anti-Obesity Prescription Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Anti-Obesity Prescription Drugs worldwide, with company and product introduction, position in the Anti-Obesity Prescription Drugs market
Market status and development trend of Anti-Obesity Prescription Drugs by types and applications
Cost and profit status of Anti-Obesity Prescription Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Anti-Obesity Prescription Drugs market as:
Global Anti-Obesity Prescription Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Anti-Obesity Prescription Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Global Anti-Obesity Prescription Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Global Anti-Obesity Prescription Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Anti-Obesity Prescription Drugs Sales Volume, Revenue, Price and Gross Margin):
VIVUS
Orexigen Therapeutics
Novo Nordisk
F Hoffmann La Roche
Arena Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Anti-Obesity Prescription Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-Obesity Prescription Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Anti-Obesity Prescription Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Anti-Obesity Prescription Drugs worldwide, with company and product introduction, position in the Anti-Obesity Prescription Drugs market
Market status and development trend of Anti-Obesity Prescription Drugs by types and applications
Cost and profit status of Anti-Obesity Prescription Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Anti-Obesity Prescription Drugs market as:
Global Anti-Obesity Prescription Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Anti-Obesity Prescription Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Global Anti-Obesity Prescription Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Global Anti-Obesity Prescription Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Anti-Obesity Prescription Drugs Sales Volume, Revenue, Price and Gross Margin):
VIVUS
Orexigen Therapeutics
Novo Nordisk
F Hoffmann La Roche
Arena Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTI-OBESITY PRESCRIPTION DRUGS
1.1 Definition of Anti-Obesity Prescription Drugs in This Report
1.2 Commercial Types of Anti-Obesity Prescription Drugs
1.2.1 Bupropion and Naltrexone
1.2.2 Orlistat
1.2.3 Lorcaserin
1.2.4 Phentermine and Topiramate
1.2.5 Liraglutide
1.3 Downstream Application of Anti-Obesity Prescription Drugs
1.3.1 Hospitals Pharmacies
1.3.2 Retail Pharmacies
1.3.3 E-commerce
1.4 Development History of Anti-Obesity Prescription Drugs
1.5 Market Status and Trend of Anti-Obesity Prescription Drugs 2013-2023
1.5.1 Global Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Anti-Obesity Prescription Drugs 2013-2017
2.2 Production Market of Anti-Obesity Prescription Drugs by Regions
2.2.1 Production Volume of Anti-Obesity Prescription Drugs by Regions
2.2.2 Production Value of Anti-Obesity Prescription Drugs by Regions
2.3 Demand Market of Anti-Obesity Prescription Drugs by Regions
2.4 Production and Demand Status of Anti-Obesity Prescription Drugs by Regions
2.4.1 Production and Demand Status of Anti-Obesity Prescription Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Anti-Obesity Prescription Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Anti-Obesity Prescription Drugs by Types
3.2 Production Value of Anti-Obesity Prescription Drugs by Types
3.3 Market Forecast of Anti-Obesity Prescription Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry
4.2 Market Forecast of Anti-Obesity Prescription Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Anti-Obesity Prescription Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Anti-Obesity Prescription Drugs by Major Manufacturers
6.2 Production Value of Anti-Obesity Prescription Drugs by Major Manufacturers
6.3 Basic Information of Anti-Obesity Prescription Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Anti-Obesity Prescription Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Anti-Obesity Prescription Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI-OBESITY PRESCRIPTION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 VIVUS
7.1.1 Company profile
7.1.2 Representative Anti-Obesity Prescription Drugs Product
7.1.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of VIVUS
7.2 Orexigen Therapeutics
7.2.1 Company profile
7.2.2 Representative Anti-Obesity Prescription Drugs Product
7.2.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
7.3 Novo Nordisk
7.3.1 Company profile
7.3.2 Representative Anti-Obesity Prescription Drugs Product
7.3.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.4 F Hoffmann La Roche
7.4.1 Company profile
7.4.2 Representative Anti-Obesity Prescription Drugs Product
7.4.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of F Hoffmann La Roche
7.5 Arena Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative Anti-Obesity Prescription Drugs Product
7.5.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
8.1 Industry Chain of Anti-Obesity Prescription Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
9.1 Cost Structure Analysis of Anti-Obesity Prescription Drugs
9.2 Raw Materials Cost Analysis of Anti-Obesity Prescription Drugs
9.3 Labor Cost Analysis of Anti-Obesity Prescription Drugs
9.4 Manufacturing Expenses Analysis of Anti-Obesity Prescription Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Anti-Obesity Prescription Drugs in This Report
1.2 Commercial Types of Anti-Obesity Prescription Drugs
1.2.1 Bupropion and Naltrexone
1.2.2 Orlistat
1.2.3 Lorcaserin
1.2.4 Phentermine and Topiramate
1.2.5 Liraglutide
1.3 Downstream Application of Anti-Obesity Prescription Drugs
1.3.1 Hospitals Pharmacies
1.3.2 Retail Pharmacies
1.3.3 E-commerce
1.4 Development History of Anti-Obesity Prescription Drugs
1.5 Market Status and Trend of Anti-Obesity Prescription Drugs 2013-2023
1.5.1 Global Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Anti-Obesity Prescription Drugs 2013-2017
2.2 Production Market of Anti-Obesity Prescription Drugs by Regions
2.2.1 Production Volume of Anti-Obesity Prescription Drugs by Regions
2.2.2 Production Value of Anti-Obesity Prescription Drugs by Regions
2.3 Demand Market of Anti-Obesity Prescription Drugs by Regions
2.4 Production and Demand Status of Anti-Obesity Prescription Drugs by Regions
2.4.1 Production and Demand Status of Anti-Obesity Prescription Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Anti-Obesity Prescription Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Anti-Obesity Prescription Drugs by Types
3.2 Production Value of Anti-Obesity Prescription Drugs by Types
3.3 Market Forecast of Anti-Obesity Prescription Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry
4.2 Market Forecast of Anti-Obesity Prescription Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Anti-Obesity Prescription Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Anti-Obesity Prescription Drugs by Major Manufacturers
6.2 Production Value of Anti-Obesity Prescription Drugs by Major Manufacturers
6.3 Basic Information of Anti-Obesity Prescription Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Anti-Obesity Prescription Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Anti-Obesity Prescription Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI-OBESITY PRESCRIPTION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 VIVUS
7.1.1 Company profile
7.1.2 Representative Anti-Obesity Prescription Drugs Product
7.1.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of VIVUS
7.2 Orexigen Therapeutics
7.2.1 Company profile
7.2.2 Representative Anti-Obesity Prescription Drugs Product
7.2.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
7.3 Novo Nordisk
7.3.1 Company profile
7.3.2 Representative Anti-Obesity Prescription Drugs Product
7.3.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.4 F Hoffmann La Roche
7.4.1 Company profile
7.4.2 Representative Anti-Obesity Prescription Drugs Product
7.4.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of F Hoffmann La Roche
7.5 Arena Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative Anti-Obesity Prescription Drugs Product
7.5.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
8.1 Industry Chain of Anti-Obesity Prescription Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
9.1 Cost Structure Analysis of Anti-Obesity Prescription Drugs
9.2 Raw Materials Cost Analysis of Anti-Obesity Prescription Drugs
9.3 Labor Cost Analysis of Anti-Obesity Prescription Drugs
9.4 Manufacturing Expenses Analysis of Anti-Obesity Prescription Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
